4.6 Article

Integrating electrochemical immunosensing and cell adhesion technologies for cancer cell detection and enumeration

Journal

ELECTROCHIMICA ACTA
Volume 286, Issue -, Pages 205-211

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.electacta.2018.08.005

Keywords

Differential pulse voltammetry; Cancer cells; Microfluidics; Point-of-care; Label-free detection

Funding

  1. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH) [P30 AR066524]
  2. Skin Diseases Research Center at the University of Wisconsin
  3. University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]

Ask authors/readers for more resources

We have successfully integrated techniques for controlling cell adhesion and performing electrochemical differential pulse voltammetry (DPV) through the use of digitally controlled microfluidics and patterned transparent indium tin oxide electrode arrays to enable rapid and sensitive enumeration of cancer cells in a scalable microscale format. This integrated approach leverages a dual-working electrode (WE) surface to improve the specificity of the detection system. Here, one of the WE surfaces is functionalized with anti-Melanocortin 1 Receptor antibodies specific to melanoma cancer cells, while the other WE acts as a control (i.e., without antibody), for detecting non-specific interactions between cells and the electrode. The method is described and shown to provide effective detection of melanoma cells at concentrations ranging between 25 and 300 cells per 20 mu L sample volume after a 5 min incubation and 15 s of DPV measurements. The estimated limit of detection was similar to 17 cells. The sensitivity and specificity of the assay were quantified using addition of large fractions of non-target cells and resulted in a detection reproducibility of similar to 97%. The proposed approach demonstrates a unique integration of electrochemical sensing and microfluidic cell adhesion technologies with multiple advantages such as label-free detection, short detection times, and low sample volumes. Next steps for this platform include testing with patient samples and use of other cell-surface biomarkers for detection and enumeration of circulating tumor cells in prostate, breast, and colon cancer. (C) 2018 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available